Real IntelligenceReviewIndependent Clinical Evaluation
Back to Atlas

Digital pathology

Ibex Breast

Ibex Medical Analytics

Analyzes digitized breast biopsy slides to support cancer detection, classification, and pathology workflow.

Designed for

Pathologist

Care setting

Pathology laboratory

Specialty

Pathology, Breast oncology

Public evidence assessedReviewed August 31, 2026

Our assessment

Bottom line

Ibex Breast has promising multisite reader and deployment evidence, but the represented public record is less mature and less independent than the evidence for some regulated pathology peers. Laboratory, scanner, specimen, and rare-pattern performance remain important limitations.

Based on public sources. RIR did not independently test this product. This is not an endorsement or recommendation.

What the evidence supports

Reviewed sources establish a real AI-assisted breast pathology product with public validation and implementation evidence.

What remains uncertain

Regulatory scope, current model performance across laboratories, and effects on diagnostic outcomes require jurisdiction- and version-specific review.

How it was studied

Public evidence includes a multisite clinical reader study comparing AI-supported primary diagnosis of breast biopsies with standard microscopy, plus clinical deployment reports in digital pathology laboratories.

Product facts

Intended use
Support pathologists reviewing digitized breast biopsy slides with case-level and slide-level AI findings.
Represented version
Current Ibex offering, formerly marketed as Galen Breast
Regulatory context
The reviewed materials describe regional regulatory availability. No uniform global authorization is implied.

Sources reviewed

3 public sources represented in this evidence profile.

Multisite Ibex Breast clinical reader studyPrimary evidenceIbex Breast product overviewOfficial productIbex Breast clinical deployment studyPrimary evidence
For clinical and investment reviewEvidence context and questions for deeper review

Evidence source base

Developer-associated reader and deployment studies. Independent peer-reviewed and local laboratory replication remain important.

Important limitation

Conference and deployment evidence does not establish performance for every specimen, biomarker, scanner, laboratory, current version, or rare histologic pattern.

Questions to ask

  1. 01Which current modules and slide scanners are authorized locally?
  2. 02How are rare lesions and borderline findings handled?
  3. 03What is the rate and consequence of AI-pathologist disagreement?
Return to AtlasHow RIR evaluates evidence